624 related articles for article (PubMed ID: 9706977)
1. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
2. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
[TBL] [Abstract][Full Text] [Related]
3. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi.
Kucher C; Zhang PJ; Pasha T; Elenitsas R; Wu H; Ming ME; Elder DE; Xu X
Am J Dermatopathol; 2004 Dec; 26(6):452-7. PubMed ID: 15618925
[TBL] [Abstract][Full Text] [Related]
4. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
Mehregan DR; Hamzavi I
Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
[TBL] [Abstract][Full Text] [Related]
5. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
6. A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas.
Bergman R; Azzam H; Sprecher E; Manov L; Munichor M; Friedman-Birnbaum R; Ben-Itzhak O
J Am Acad Dermatol; 2000 Mar; 42(3):496-500. PubMed ID: 10688724
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi.
Busam KJ; Granter SR; Iversen K; Jungbluth AA
Am J Dermatopathol; 2000 Jun; 22(3):237-41. PubMed ID: 10871066
[TBL] [Abstract][Full Text] [Related]
8. Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours.
Orosz Z
Histopathology; 1999 Jun; 34(6):517-25. PubMed ID: 10383696
[TBL] [Abstract][Full Text] [Related]
9. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
King R; Googe PB; Weilbaecher KN; Mihm MC; Fisher DE
Am J Surg Pathol; 2001 Jan; 25(1):51-7. PubMed ID: 11145251
[TBL] [Abstract][Full Text] [Related]
10. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
Melanoma Res; 1998 Aug; 8(4):337-43. PubMed ID: 9764809
[TBL] [Abstract][Full Text] [Related]
11. Expression of Melan-A in Spitz, pigmented spindle cell nevi, and congenital nevi: comparative immunohistochemical study.
Evans MJ; Sanders DS; Grant JH; Blessing K
Pediatr Dev Pathol; 2000; 3(1):36-9. PubMed ID: 10644168
[TBL] [Abstract][Full Text] [Related]
12. Differentiating neurotized melanocytic nevi from neurofibromas using Melan-A (MART-1) immunohistochemical stain.
Chen Y; Klonowski PW; Lind AC; Lu D
Arch Pathol Lab Med; 2012 Jul; 136(7):810-5. PubMed ID: 22742554
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors.
Rasic D; Korsgaard N; Marcussen N; Precht Jensen EM
Ann Diagn Pathol; 2023 Dec; 67():152211. PubMed ID: 37717457
[TBL] [Abstract][Full Text] [Related]
14. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45.
Heegaard S; Jensen OA; Prause JU
Melanoma Res; 2000 Aug; 10(4):350-4. PubMed ID: 10985669
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas.
Chen PL; Chen WS; Li J; Lind AC; Lu D
Mod Pathol; 2013 Jan; 26(1):44-53. PubMed ID: 22899289
[TBL] [Abstract][Full Text] [Related]
17. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants.
Blessing K; Sanders DS; Grant JJ
Histopathology; 1998 Feb; 32(2):139-46. PubMed ID: 9543670
[TBL] [Abstract][Full Text] [Related]
18. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
19. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis.
El Shabrawi-Caelen L; Kerl H; Cerroni L
Am J Dermatopathol; 2004 Oct; 26(5):364-6. PubMed ID: 15365366
[TBL] [Abstract][Full Text] [Related]
20. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
